EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Advances in N ‐ and S ‐Heterocycles as c‐Jun‐N‐Terminal Kinase 3 Inhibitors for Alzheimer's Disease Treatment

Parul Yadav iD, Deepak Mishra iD, Ram Singh iD

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70381 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 16.09.2026. Verfasst von Parul Yadav und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Chemistry, Delhi Technological University, Delhi, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Mitogen-Activated Protein Kinase 10, Protein Kinase Inhibitors, Heterocyclic Compounds. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

c‐Jun‐N‐terminal kinase 3 (JNK3) inhibitors are emerging as promising therapeutic agents for the treatment of Alzheimer's disease (AD). Predominantly expressed in the central nervous system (CNS), JNK3 plays a crucial role in neuronal apoptosis and inflammation, processes that are often dysregulated in neurodegenerative conditions. In recent years, a diverse range of heterocycle scaffolds has been explored as selective JNK3 inhibitors, demonstrating significant potential in modulating disease pathology. Structure–activity relationship (SAR) studies have further facilitated the rational design and optimization of these compounds, improving their potency, selectivity, and pharmacokinetic profiles. By selectively inhibiting JNK3, these small compounds can mitigate neuroinflammation and promote neuronal survival. The development of small molecule JNK3 inhibitors offers a targeted approach that may minimize side effects. This article explores various heterocyclic molecules such as pyrazoles, thiazoles, imidazoles, and thiophenes, evaluated for JNK3 inhibition. This review will help medicinal chemists to design and develop new molecules based on established data on isoform‐selective JNK3 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMitogen-Activated Protein Kinase 10Protein Kinase InhibitorsHeterocyclic CompoundsHumansAnimalsStructure-Activity RelationshipDrug Design

Stichwörter der Autor:innen

Alzheimer's diseaseJNK3 inhibitorsN‐heterocyclesS‐heterocyclesneurodegeneration

Substanzen

Mitogen-Activated Protein Kinase 10Protein Kinase InhibitorsHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Applied Chemistry, Delhi Technological University, Delhi, India.

ORCID-Profile: Parul Yadav, Deepak Mishra, Ram Singh

Zitieren

APA

Yadav, P., Mishra, D., & Singh, R. (2026). Advances in N ‐ and S ‐Heterocycles as c‐Jun‐N‐Terminal Kinase 3 Inhibitors for Alzheimer's Disease Treatment. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70381

Vancouver

Yadav P, Mishra D, Singh R. Advances in N ‐ and S ‐Heterocycles as c‐Jun‐N‐Terminal Kinase 3 Inhibitors for Alzheimer's Disease Treatment. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70381

BibTeX
@article{Yadav2026,
  author = {Yadav, Parul and Mishra, Deepak and Singh, Ram},
  title = {Advances in N ‐ and S ‐Heterocycles as c‐Jun‐N‐Terminal Kinase 3 Inhibitors for Alzheimer's Disease Treatment},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70381}
}
Kostenlos starten →